Can CBD oil help with Parkinson's?

Parkinson’s Disease is a neurological condition that causes the deterioration of dopamine-producing cells in the brain, which in turn causes a range of symptoms that can be categorised into two forms: motor symptoms and non-motor symptoms. It’s thought to affect 10 million people worldwide. 

In this article, we look at recent research on using CBD to treat Parkinson’s, what studies have revealed, and what more needs to be done before we can be sure. 

What the research says so far

Studies into the use of non-intoxicating CBD for a variety of health conditions show it may help some patients living with certain conditions. Specifically, we’re going to be looking at studies in Parkinson’s patients. 

A scientific review of the use of CBD for treating Parkinson’s in 2024 focused on existing evidence to provide a comprehensive overview of the efficacy of CBD in treating Parkinson’s. Preclinical animal studies “demonstrated promising results regarding CBD’s potential benefits in PD,” suggesting cannabinoids like CBD “can modulate the ECS, influence neurochemical changes in different systems, and potentially offer neuroprotective effects in PD.” However, while this may seem promising, what works in animals does not always carry over to humans. Currently, human trials are limited, and of the seven reviewed, they yielded inconsistent results, highlighting the need for further study.

A more recent 2026 Australian review explains, “preclinical studies suggest potential neuroprotective, anti-inflammatory, and antioxidant benefits in laboratory and animal models” regarding CBD. It does, however, also outline the potential risks associated with CBD, especially regarding interactions with other medications, but these can vary because of administration, individual tolerance, and dosage. Overall, the review concludes “preclinical studies investigating the effects of CBD in PD have demonstrated predominantly positive outcomes.” However, clinical trials have yielded inconsistent results, further demonstrating the gap in the literature and the need for further study.

Another 2026 conference overview evaluating cannabis-based interventions in Parkinson’s disease screened 975 research items, six meta-analyses of clinical trials and preclinical studies, and randomised controlled trials. The compiled data revealed, “certain cannabinoid formulations may offer symptomatic relief for patients with Parkinson’s disease.” It also notes “preclinical studies have shown promising results,” but that “further well-designed clinical research is essential.”

Overall, the research seems to say the same thing. CBD has shown promise for Parkinson’s in the preclinical stages, but more research and double-blind, placebo-controlled clinical trials are needed to understand the true efficacy. 

Which symptoms have research looked at?

There is plenty of research into different aspects of treating Parkinson’s with CBD, but the above studies predominantly focus on creating an overview of the impact on both motor and nonmotor symptoms.

These studies reviewed results on the effect of CBD on motor symptoms, pain, depression, anxiety, sleep disturbances, psychosis, and quality of life in patients living with Parkinson’s. However, they were compiled using existing data from both preclinical animal and human trials, which were inconsistent, and highlighted the need for more specific and well–structured trials to evaluate CBD’s efficacy in treating Parkinson disease.

A particular area of interest from the 2024 review explored CBD for Levodopa-induced dyskinesia (LID), a condition commonly seen in PD patients treated with Levodopa. However, it notes that the few studies into the effects of cannabis or CBD for motor dysfunctions (like LID) have produced contradictory results.

There are more specific studies into the application of CBD for Parkinson’s symptoms, such as a 2024 randomised clinical trial into CBD for Seborrheic Dermatitis, a skin condition thought to affect 18.6% to 59% of individuals living with Parkinson disease. While the results from the 53 participants showed the change in motor symptoms was “not statistically significant,” they did highlight estimated improvement in quality of life in the CBD group versus estimated worsening in the placebo group. However, this trial did use an extract with some THC in it. 

How is CBD Oil taken?

There is no one-size-fits-all CBD dosage for individuals living with Parkinson’s. Factors like age, weight, metabolism, and gender influence CBD absorption, and once in the body, cannabinoids like CBD can interact with certain prescription medications.

While studies have used between 150 and 300 mg for research purposes, Parkinson’s patients are advised to start with a low dosage that can be gradually increased until the optimal result is achieved. This may require some trial and error to achieve maximum therapeutic benefit with minimal side effects.

When starting any type of cannabinoid therapy, the need for a full and in-depth discussion with a doctor who is registered and experienced in prescribing cannabinoids is paramount. Only they can advise you on the right dosages and methods of administration for your unique circumstances.

Different application techniques affect the speed of CBD absorption and therefore, the emergence of its effects:

• CBD oils for sublingual (under the tongue) administration: cannabinoid contents are absorbed through the lining of the mouth and directly into the bloodstream, and therapeutic effects can occur within minutes.

• CBD for inhalation: these are designed to be vaped and inhaled, allowing quick absorption and access to the brain.

• Topical CBD products: designed to permeate the skin layer by layer and interact with the receptors in the skin.

• Edible CBD products: these must pass through the stomach, intestines and liver before becoming ‘activated’, so their effects on the body are delayed.

Those new to CBD are advised to stick with one type of product when consuming CBD for the first time, to ease dosage calculations and administration.

Side effects and Parkinson’s medicines

While pure CBD does not appear to cause harm, according to the World Health Organisation, there are some risks and side effects associated with its use. 

Certain medications can interact with CBD, leading to negative effects, which is why those taking medication are advised to avoid CBD by the FSA unless under medical direction. 

For those living with Parkinson’s disease, this is particularly important (particularly in elderly patients) as medication management for the condition is already complex. Combining Parkinson’s medications with CBD can exacerbate side effects, including: 

• dizziness

• drowsiness

• confusion

• difficulty concentrating

Other possible side effects of CBD can include: 

• Dry mouth

• Feeling light-headed

• Changes in appetite (often decreased)

• Gastrointestinal upset

• Fatigue or drowsiness

• Changes in mood

Always seek medical advice from your doctor or a healthcare professional so you can receive recommendations tailored to you and reduce the risk of adverse reactions.

Can you get medical cannabis for Parkinson’s in the UK? 

Yes, you can, but it depends on the route you take.

The NHS is only likely to prescribe cannabis-based products for medicinal purposes for rare, severe forms of epilepsy, chemotherapy-induced nausea and vomiting, and muscle stiffness or spasticity from multiple sclerosis. This means getting medical cannabis for Parkinson’s is highly unlikely on the NHS.

That said, Parkinson’s is one of the qualifying conditions for medical cannabis treatment from a private clinic, like Releaf. All you need for this route is a Parkinson’s diagnosis and evidence of two or more treatments you’ve tried to manage your symptoms. If you choose this route, one of our prescribing specialists can determine the most suitable medication for your symptoms and oversee your treatment, including dosage and help to minimise side effects.

Using medical cannabis for Parkinson’s is not a new idea, although the lack of clinical studies may make you think otherwise. Research is still ongoing, though, so we'll see what results emerge in the coming year.

FAQS

Is CBD oil effective in treating Parkinson’s Disease?

To be clear, CBD is not considered a cure for Parkinson’s, and while the available research shows promise, it’s hard to give a definitive answer without more evidence from human clinical trials.

Can CBD stop tremors?

Currently, there is no conclusive clinical evidence that CBD can help with tremors, either from Parkinson’s or other neurological conditions, like essential tremor.

A double-blind trial in 2014 into the effects of CBD in 21 PD patients without dementia or comorbid psychiatric conditions found no significant difference in motor score, but the author noted a possible improvement in quality of life from the 300 mg group. However, this study was broad, covering various aspects of living with Parkinson’s, and used a narrow patient group, but it highlights interesting areas for further study.

Does CBD oil interact with Parkinson’s medications?

Yes, CBD has been shown to interact with certain medications, including some common Parkinson’s medications.

Speak to your specialist or pharmacist about any medications you are taking, as some medications can interact with CBD.

In Summary

While there is evidence to suggest the potential of CBD in treating Parkinson’s disease, there are not enough clinical trials to truly determine its efficacy.

What’s more, the amount of CBD required to achieve the desired effects is individualised and varies between patients, and so it is essential to speak with a medical professional before starting any type of cannabinoid therapy.

Accessing medical cannabis can be challenging due to the stigma surrounding it. However, Releaf makes it simple with our tailored monthly packages, specialist consultations for medical cannabis, and a medical cannabis card for peace of mind, all based on your cannabis prescription. Or use our free online medical cannabis eligibility checker to see whether you qualify in under 2 minutes.

Releaf - Redefining healthcare